Salt LickPersonalised screening
Risk assessment tailored to Indian demographics and genetics, not borrowed from populations it was never built for.
Intelligence to Intercept
A national-scale, AI-enabled cancer preventive platform
Early risk assessment and cancer prevention, designed to support government cancer control goals and deliver measurable impact at scale.
NPCDCS
National Health Mission
PM-JAY
An Esperer Group company
Prevention, not reaction
Traditional healthcare systems focus on treatment after the disease appears. Salt Lick changes the paradigm by identifying high-risk individuals before symptomatic cancer develops.
Through AI-powered predictive analytics, community screening infrastructure and integrated referral systems, Salt Lick aims to significantly improve late-stage cancer detection and survival outcomes.
Early assessment
High-risk individuals identified and prioritised, so limited diagnostic capacity reaches the people who need it first.
Preventive intervention
Referral and follow-up before symptom onset, connecting assessment to the clinics and programmes that act on it.
The experience
A look at how screening, assessment and referral come together on the ground.
Film — English
add
add
assets/film-en.mp4Film — हिंदी
add
add
assets/film-hi.mp4Indian innovation, built for India
Salt Lick Healthcare Pvt Ltd, headquartered in Mumbai, is a proud Esperer Group company dedicated to transformative cancer care.
As an Indian innovation powerhouse supported by the Government of India, the company has earned global recognition through its pioneering cancer nutrition solutions, backed by multiple international patents.
Adding to that work, Salt Lick Healthcare has developed an AI-enabled cancer risk assessment facility tailored for the Indian population, enabling early detection and personalised prevention strategies rooted in local demographics and genetics.
Headquartered in Mumbai
An Esperer Group company, working with government cancer control programmes nationwide.
Internationally patented
Multiple international patents across cancer nutrition and molecular intervention.
Built on Indian data
Risk models developed for Indian demographics and genetics rather than adapted after the fact.
Meet the team
Research, clinical practice and healthcare delivery at national scale.
Founder
Dr. Raktim Chattopadhyay
A distinguished cancer researcher with a PhD in Cancer Biology, Dr Chattopadhyay has made significant contributions to the field, notably through his groundbreaking work on the gut microbiota–cancer relationship via the DiNI Axis. His research, backed by global patents and peer-reviewed publications, focuses on molecular nutrition, precision oncology and translational interventions that enhance patient outcomes alongside conventional therapies.
As a serial entrepreneur, he has built multiple ventures in oncology nutrition and biotechnology, including the Esperer Group. At Salt Lick Healthcare he integrates technology with evidence-based clinical solutions to make advanced diagnostics, supportive care and holistic cancer management more accessible and scalable, especially in emerging markets.
LinkedIn
Chief Executive Officer
Mr. Himanshu Dave
- Strategic healthcare leader with over 35 years across pharmaceuticals and public health systems.
- Architect of scalable healthcare delivery models integrating private-sector innovation with public health priorities.
- Led the creation of India's largest rural free-dialysis network, expanding lifesaving access to nearly one-third of the nation's population.
Leadership footprint: Wockhardt · Astellas · Fairfax Financial Holdings (Foundation)
LinkedInLet's work together to create a difference
For partnerships, government programmes and screening deployments.